Report of the 17th Nationwide Followâ€up Survey of Pr

Hepatology Research 37, 676-691

DOI: 10.1111/j.1872-034x.2007.00119.x

Citation Report

#	Article	IF	CITATIONS
1	First International Symposium of Current Issues for Nationwide Survey of Primary Liver Cancer in Korea, Taiwan and Japan. Japanese Journal of Clinical Oncology, 2007, 37, 233-240.	0.6	4
2	Surgical Outcome and Prognostic Factors in Intrahepatic Cholangiocarcinoma. World Journal of Surgery, 2008, 32, 2675-2680.	0.8	89
3	Standards und neue Aspekte der Diagnostik und Therapie des hepatozellulän Karzinoms. Onkopipeline, 2008, 1, 109-119.	0.0	0
4	Comparative study of the Japan Integrated Stage (JIS) and modified JIS score as a predictor of survival after hepatectomy for hepatocellular carcinoma. Journal of Gastroenterology, 2008, 43, 369-377.	2.3	12
5	Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patients. Journal of Gastroenterology, 2008, 43, 975-981.	2.3	26
6	Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis. British Journal of Cancer, 2008, 98, 1161-1165.	2.9	50
7	Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors. Liver International, 2008, 28, 1256-1263.	1.9	121
8	Neither Multiple Tumors Nor Portal Hypertension Are Surgical Contraindications for Hepatocellular Carcinoma. Gastroenterology, 2008, 134, 1908-1916.	0.6	645
9	Gain of GRHL2 is associated with early recurrence of hepatocellular carcinoma. Journal of Hepatology, 2008, 49, 746-757.	1.8	57
10	Alcohol Drinking and Liver Cancer Risk: An Evaluation Based on a Systematic Review of Epidemiologic Evidence among the Japanese Population. Japanese Journal of Clinical Oncology, 2008, 38, 816-838.	0.6	58
11	Pancreatic Metastasis from Renal Cell Carcinoma with Intraportal Tumor Thrombus. Internal Medicine, 2008, 47, 1967-1970.	0.3	22
12	Intrahepatic Cholangiocarcinoma. Annals of Surgery, 2008, 248, 84-96.	2.1	729
13	Clinicopathological examination of nonalcoholic steatohepatitis (NASH) leading to hepatocellular carcinoma (HCC). Acta Hepatologica Japonica, 2009, 50, 626-633.	0.0	3
14	Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Annals of Oncology, 2009, 20, 1589-1595.	0.6	148
15	Interaction between cytochrome P450 1A2 genetic polymorphism and cigarette smoking on the risk of hepatocellular carcinoma in a Japanese population. Carcinogenesis, 2009, 30, 1729-1734.	1.3	36
17	Hepatocellular carcinoma occurring in a young Crohn's disease patient. Pathology International, 2009, 59, 492-496.	0.6	15
18	Predeposit Autologous Plasma Donation in Liver Resection for Hepatocellular Carcinoma: Toward Allogenic Blood-Free Operations. Journal of the American College of Surgeons, 2009, 209, 206-214.	0.2	11
19	Frequent detection of hepatitis B virus DNA in hepatocellular carcinoma of patients with sustained virologic response for hepatitis C virus. Journal of Medical Virology, 2009, 81, 1009-1014.	2.5	31

#	ARTICLE	IF	CITATIONS
20	Hepatic resection for hepatocellular carcinoma in the elderly. Journal of Surgical Oncology, 2009, 99, 154-160.	0.8	71
21	Epidemiology of hepatocellular carcinoma in Japan. Journal of Gastroenterology, 2009, 44, 102-107.	2.3	181
22	Image-guided percutaneous ablation therapies for hepatocellular carcinoma. Journal of Gastroenterology, 2009, 44, 122-131.	2.3	28
23	Is Liver Resection Justified in Advanced Hepatocellular Carcinoma? Results of an Observational Study in 464 Patients. Journal of Gastrointestinal Surgery, 2009, 13, 1313-1320.	0.9	69
24	Intrahepatic cholangiocarcinoma with micrometastasis in the portal tract of the liver. Clinical Journal of Gastroenterology, 2009, 2, 306-309.	0.4	1
25	Surgical treatment of hepatocellular carcinoma. Surgery Today, 2009, 39, 833-843.	0.7	38
26	Significance of dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expressions in hepatocellular carcinoma. Hepatology Research, 2009, 39, 274-281.	1.8	9
27	Radiofrequency Ablation Combined with Chemoembolization for the Treatment of Hepatocellular Carcinomas Larger than 5 cm. Journal of Vascular and Interventional Radiology, 2009, 20, 217-224.	0.2	65
28	Reconsideration of splenectomy for cirrhotic patients -Tracing the history and pitfalls Acta Hepatologica Japonica, 2010, 51, 205-218.	0.0	6
29	Risk factors for postoperative recurrence of nonâ€B non hepatocellular carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, 2010, 17, 291-295.	1.4	8
30	Surgical technique: new advances for expanding indications and increasing safety in liver resection for HCC. Journal of Hepato-Biliary-Pancreatic Sciences, 2010, 17, 389-393.	1.4	29
31	Interventional oncology: new options for interstitial treatments and intravascular approaches. Journal of Hepato-Biliary-Pancreatic Sciences, 2010, 17, 407-409.	1.4	40
32	Single HCC between 2 and 5 cm: the grey zone. Journal of Hepato-Biliary-Pancreatic Sciences, 2010, 17, 434-437.	1.4	3
33	Etiology of liver cirrhosis in Japan: a nationwide survey. Journal of Gastroenterology, 2010, 45, 86-94.	2.3	130
34	Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatology International, 2010, 4, 439-474.	1.9	944
35	Surveillance for Hepatocellular Carcinoma Improves Survival in Asian-American Patients with Hepatitis B: Results from a Community-Based Clinic. Digestive Diseases and Sciences, 2010, 55, 826-835.	1.1	43
36	Clinical presentation and management of intrahepatic cholangiocarcinoma. Gastroenterologie Clinique Et Biologique, 2010, 34, 191-199.	0.9	39
37	Excellent outcomes with angiographic subsegmentectomy in the treatment of typical hepatocellular carcinoma. Cancer, 2010, 116, 393-399.	2.0	27

#	ARTICLE	IF	Citations
38	Midterm outcomes in patients with intermediateâ€sized hepatocellular carcinoma. Cancer, 2010, 116, 5452-5460.	2.0	283
39	Preoperative estimation of remnant hepatic function using fusion images obtained by 99mTc-labelled galactosyl-human serum albumin liver scintigraphy and computed tomography. British Journal of Surgery, 2010, 97, 934-944.	0.1	47
40	Risk factors for intrahepatic cholangiocarcinoma: a possible role of hepatitis B virus. Journal of Viral Hepatitis, 2010, 17, 742-748.	1.0	41
41	The 2008 Okuda lecture: Management of hepatocellular carcinoma: From surveillance to molecular targeted therapy. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 439-452.	1.4	98
42	Liver transplantation and conventional surgery for advanced hepatocellular carcinoma. Transplant International, 2010, 23, 723-727.	0.8	44
43	Liver Cancer Working Group Report. Japanese Journal of Clinical Oncology, 2010, 40, i19-i27.	0.6	65
44	Changing Trends in Hepatitis C Infection over the Past 50 Years in Japan. Intervirology, 2010, 53, 39-43.	1.2	147
45	Neoplasms of the hepatobiliary system: clinical presentation, molecular pathways and diagnostics. Expert Review of Molecular Diagnostics, 2010, 10, 883-895.	1.5	8
46	Management of Hepatocellular Carcinoma: From Prevention to Molecular Targeted Therapy. Oncology, 2010, 78, 1-6.	0.9	17
47	Radiofrequency Ablation for Hepatocellular Carcinoma: Updated Review in 2010. Oncology, 2010, 78, 113-124.	0.9	134
48	Chemoembolization for Unresectable Hepatocellular Carcinoma in Japan. Oncology, 2010, 78, 135-141.	0.9	12
49	Hepatic Arterial Infusion Chemotherapy Using Low-Dose 5-Fluorouracil and Cisplatin for Advanced Hepatocellular Carcinoma. Oncology, 2010, 78, 148-153.	0.9	87
50	Report of the 18th followâ€up survey of primary liver cancer in Japan. Hepatology Research, 2010, 40, 1043-1059.	1.8	120
51	Chapter 3: Surgery. Hepatology Research, 2010, 40, 48-73.	1.8	3
52	Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatology Research, 2010, 40, 667-685.	1.8	154
53	Efficacy and safety of radiofrequency ablation for elderly hepatocellular carcinoma patients. Hepatology Research, 2010, 40, 997-1005.	1.8	60
54	Radiofrequency ablation is justified for elderly patients with hepatocellular carcinoma. Hepatology Research, 2010, 40, 954-955.	1.8	1
55	Compensatory enlargement of the liver after treatment of hepatocellular carcinoma with carbon ion radiotherapy – Relation to prognosis and liver function. Radiotherapy and Oncology, 2010, 96, 236-242.	0.3	30

#	Article	IF	CITATIONS
56	Comparison of efficacy and toxicity of short-course carbon ion radiotherapy for hepatocellular carcinoma depending on their proximity to the porta hepatis. Radiotherapy and Oncology, 2010, 96, 231-235.	0.3	73
57	Increased fecal leukocytes may reflect resolution of IBD. Scandinavian Journal of Gastroenterology, 2011, 46, 251-252.	0.6	0
58	Radiotherapeutic Strategies in the Management of Hepatocellular Carcinoma. Oncology, 2011, 81, 123-133.	0.9	24
59	Hepatocellular Carcinoma in 2011 and Beyond: From the Pathogenesis to Molecular Targeted Therapy. Oncology, 2011, 81, 1-10.	0.9	23
60	Conventional Surgical Treatment ofÂHepatocellular Carcinoma. Clinics in Liver Disease, 2011, 15, 353-370.	1.0	19
61	Characteristics of Patients With Nonalcoholic Steatohepatitis Who Develop Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2011, 9, 428-433.	2.4	358
62	Role of dihydropyrimidine dehydrogenase and thymidylate synthase expression in immunohistochemistry of intrahepatic cholangiocarcinoma. Hepatology Research, 2011, 41, 64-70.	1.8	7
63	Longâ€ŧerm outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine. Hepatology Research, 2011, 41, 405-416.	1.8	39
64	Molecular characteristics of nonâ€cancerous liver tissue in nonâ€B nonâ€C hepatocellular carcinoma. Hepatology Research, 2011, 41, 711-721.	1.8	25
65	Demonstration of quality of care measurement using the Japanese liver cancer registry. Hepatology Research, 2011, 41, 1208-1215.	1.8	17
66	Continuous Improvement of Survival Outcomes of Resection of Hepatocellular Carcinoma. Annals of Surgery, 2011, 253, 745-758.	2.1	313
67	Influence of Surgical Margins on Outcome in Patients With Intrahepatic Cholangiocarcinoma. Annals of Surgery, 2011, 254, 824-830.	2.1	215
68	Analysis of Survival in Very Early Hepatocellular Carcinoma After Resection. Journal of Clinical Gastroenterology, 2011, 45, 366-371.	1.1	16
69	High TSC22D3 and low GBP1 expression in the liver is a risk factor for early recurrence of hepatocellular carcinoma. Experimental and Therapeutic Medicine, 2011, 2, 425-431.	0.8	12
70	Utility of contrastâ€enhanced ultrasonography with Sonazoid in radiofrequency ablation for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 759-764.	1.4	75
71	Comparison of the prognostic accuracy of the sixth and seventh editions of the TNM classification for intrahepatic cholangiocarcinoma. Hpb, 2011, 13, 198-205.	0.1	19
72	Pathological spectrum of intrahepatic cholangiocarcinoma arising in nonâ€biliary chronic advanced liver diseases. Pathology International, 2011, 61, 298-305.	0.6	33
7 3	Small intestinal metastasis from intrahepatic cholangiocarcinoma: Report of a case. Surgery Today, 2011, 41, 859-864.	0.7	8

#	Article	IF	Citations
74	Surgical outcomes of intrahepatic cholangiocarcinoma. Surgery Today, 2011, 41, 896-902.	0.7	70
75	Surgical treatment of lymph node metastases from hepatocellular carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, 2011, 18, 559-566.	1.4	41
76	Analysis of risk factors for hyperbilirubinemia occurring after hepatectomy. Journal of Hepato-Biliary-Pancreatic Sciences, 2011, 18, 724-730.	1.4	7
77	Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis. Abdominal Imaging, 2011, 36, 264-272.	2.0	180
78	The current role of minimally invasive therapies in the management of liver tumors. Abdominal Imaging, 2011, 36, 635-647.	2.0	23
79	Long-term surviving patient with inferior vena cava tumor thrombus and extrahepatic metastasis after spontaneous ruptured hepatocellular carcinoma. Clinical Journal of Gastroenterology, 2011, 4, 123-128.	0.4	3
80	AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma. Cancer, 2011, 117, 2170-2177.	2.0	183
81	Prevention of intrahepatic distant recurrence by transcatheter arterial infusion chemotherapy with platinum agents for stage I/II hepatocellular carcinoma. Cancer, 2011, 117, 4018-4025.	2.0	20
82	Randomized, Phase II Study Comparing Interferon Combined with Hepatic Arterial Infusion of Fluorouracil plus Cisplatin and Fluorouracil Alone in Patients with Advanced Hepatocellular Carcinoma. Oncology, 2011, 81, 281-290.	0.9	64
83	Accelerated progression of hepatocellular carcinoma with cytokeratin 19 expression during treatment with lamivudine for hepatitis B virus-related liver cirrhosis. Scandinavian Journal of Gastroenterology, 2011, 46, 249-251.	0.6	5
84	The Impact of CT Follow-Up Interval on Stages of Hepatocellular Carcinomas Detected During the Surveillance of Patients With Liver Cirrhosis. American Journal of Roentgenology, 2012, 199, 816-821.	1.0	6
85	Obesity and Liver Cancer Risk: An Evaluation Based on a Systematic Review of Epidemiologic Evidence Among the Japanese Population. Japanese Journal of Clinical Oncology, 2012, 42, 212-221.	0.6	46
86	A case of poorly differentiated hepatocellular carcinoma with intriguing ultrasonography findings. Oncology Letters, 2012, 4, 393-397.	0.8	7
87	A Rare Case of Hepatocellular Carcinoma Accompanied by Metastasis of a Cervical Lymph Node. Internal Medicine, 2012, 51, 381-385.	0.3	11
88	Mortality and morbidity of hepatectomy, radiofrequency ablation, and embolization for hepatocellular carcinoma: a national survey of 54,145 patients. Journal of Gastroenterology, 2012, 47, 1125-1133.	2.3	100
89	Novel Lens culinaris agglutinin-reactive fraction of $\hat{l}\pm$ -fetoprotein: a biomarker of hepatocellular carcinoma recurrence in patients with low $\hat{l}\pm$ -fetoprotein concentrations. International Journal of Clinical Oncology, 2012, 17, 373-379.	1.0	24
90	Liver Resection for Hepatocellular Carcinoma ≧ cm: Results of an Italian Multicenter Study on 588 Patients. Journal of the American College of Surgeons, 2012, 215, 244-254.	0.2	51
91	Multidetector CT Features of Mesenteric Vein Thrombosis. Radiographics, 2012, 32, 1503-1522.	1.4	56

#	Article	IF	CITATIONS
92	Postoperative adjuvant transcatheter arterial chemoembolisation improves survival of intrahepatic cholangiocarcinoma patients with poor prognostic factors: Results of a large monocentric series. European Journal of Surgical Oncology, 2012, 38, 602-610.	0.5	44
93	Periductal infiltrating type of intrahepatic cholangiocarcinoma: a rare macroscopic type without any apparent mass. Surgery Today, 2012, 42, 1189-1194.	0.7	25
94	Current Status of Hepatocellular Carcinoma Treatment in Japan. Clinical Drug Investigation, 2012, 32, 15-23.	1.1	9
95	Molecular Targeted Therapy for Growth Factors in Hepatocellular Carcinoma. , 2012, , .		0
96	The influence of postoperative glycemic control on recurrence after curative resection in diabetics with hepatitis C virusâ€related hepatocellular carcinoma. Journal of Surgical Oncology, 2012, 105, 606-611.	0.8	16
97	Alcohol drinking and primary liver cancer: A pooled analysis of four Japanese cohort studies. International Journal of Cancer, 2012, 130, 2645-2653.	2.3	39
98	Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis. British Journal of Surgery, 2012, 99, 855-863.	0.1	130
99	Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis (Br J Surg 2012; 99: 855–863). British Journal of Surgery, 2012, 99, 863-863.	0.1	2
100	Resection of segment VIII for hepatocellular carcinoma. British Journal of Surgery, 2012, 99, 1105-1112.	0.1	24
101	Guidelines on nutritional management in Japanese patients with liver cirrhosis from the perspective of preventing hepatocellular carcinoma. Hepatology Research, 2012, 42, 621-626.	1.8	37
102	Health-related quality of life in patients with hepatocellular carcinoma after hepatic resection, transcatheter arterial chemoembolization, radiofrequency ablation or no treatment. Surgical Oncology, 2012, 21, e23-e30.	0.8	67
103	Salvage Hepatectomy for Local Recurrent Hepatocellular Carcinoma After Ablation Therapy. Annals of Surgical Oncology, 2012, 19, 2238-2245.	0.7	23
104	Palliative radiation therapy for pulmonary metastases from hepatocellular carcinoma. Clinical and Experimental Metastasis, 2012, 29, 197-205.	1.7	29
105	Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Radiation Oncology, 2013, 8, 15.	1.2	25
106	Single-step multimodal locoregional treatment for unresectable hepatocellular carcinoma: balloon-occluded percutaneous radiofrequency thermal ablation (BO-RFA) plus transcatheter arterial chemoembolization (TACE). Radiologia Medica, 2013, 118, 555-569.	4.7	24
107	DNA hypermethylation of zygote arrest 1 (ZAR1) in hepatitis C virus positive related hepatocellular carcinoma. SpringerPlus, 2013, 2, 150.	1.2	12
108	680 CLINICAL CHARACTERISTICS, TREATMENT AND PROGNOSIS OF NON-B NON-C HEPATOCELLULAR CARCINOMA: A LARGE RETROSPECTIVE MULTICENTER COHORT STUDY. Journal of Hepatology, 2013, 58, S276.	1.8	2
109	Intrahepatic Cholangiocarcinoma: Management Options and Emerging Therapies. Journal of the American College of Surgeons, 2013, 217, 736-750e4.	0.2	134

#	Article	IF	CITATIONS
110	A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma. Radiation Oncology, 2013, 8, 239.	1.2	28
111	Surgical Outcomes and Clinical Characteristics of Elderly Patients Undergoing Curative Hepatectomy for Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2013, 17, 1929-1937.	0.9	30
112	Clinical features of hepatocellular carcinoma in patients with autoimmune hepatitis in Japan. Journal of Gastroenterology, 2013, 48, 109-114.	2.3	31
113	Prospective Study of Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: An Asian Cooperative Study between Japan and Korea. Journal of Vascular and Interventional Radiology, 2013, 24, 490-500.	0.2	73
114	Hepatic and Extrahepatic Malignancies in Cirrhosis Caused by Nonalcoholic Steatohepatitis and Alcoholic Liver Disease. Alcoholism: Clinical and Experimental Research, 2013, 37, E247-52.	1.4	34
115	Systematic review: Asian patients with chronic hepatitis C infection. Alimentary Pharmacology and Therapeutics, 2013, 37, 921-936.	1.9	105
116	Biomarkers: Evaluation of Screening for and Early Diagnosis of Hepatocellular Carcinoma in Japan and China. Liver Cancer, 2013, 2, 31-39.	4.2	90
117	Hepatocarcinogenesis in nonâ€alcoholic fatty liver disease in <scp>J</scp> apan. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 88-92.	1.4	42
118	Giant Hepatic Cyst with Septal Structure: Diagnosis and Management. International Journal of Hepatology, 2013, 2013, 1-6.	0.4	14
119	Outcomes after hepatic resection and subsequent multimodal treatment of recurrence for multifocal hepatocellular carcinoma. British Journal of Surgery, 2013, 100, 1516-1522.	0.1	29
120	Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. British Journal of Cancer, 2013, 109, 1904-1907.	2.9	132
121	Body Mass Index and Weight Change During Adulthood Are Associated With Increased Mortality From Liver Cancer: The JACC Study. Journal of Epidemiology, 2013, 23, 219-226.	1.1	13
122	Hepatobiliary Malignancies: Lessons from Asia. Digestive Diseases, 2013, 31, 130-137.	0.8	10
123	Surgical resection for hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2013, 25, 912-919.	0.8	30
124	Can Hepatocellular Carcinoma (HCC) Produce Unconventional Metastases? Four Cases of Extrahepatic HCC. Tumori, 2013, 99, e19-e23.	0.6	14
125	Treatment for Hepatocellular Carcinoma in Elderly Patients: A Literature Review. Journal of Cancer, 2013, 4, 635-643.	1.2	90
126	Transcatheter Arterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Clinical Outcome and Safety in Elderly Patients. Journal of Cancer, 2014, 5, 590-597.	1.2	22
127	Latin American Association for the Study of the Liver (LAASL) Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Annals of Hepatology, 2014, 13, S4-S40.	0.6	34

#	ARTICLE	IF	Citations
128	Diabetes Mellitus and Liver Cancer Risk: An Evaluation Based on a Systematic Review of Epidemiologic Evidence among the Japanese Population. Japanese Journal of Clinical Oncology, 2014, 44, 986-999.	0.6	28
129	Hepatic resection associated with good survival for selected patients with multinodular hepatocellular carcinoma. Tumor Biology, 2014, 35, 8355-8358.	0.8	17
130	Factors associated with early cancerâ€related death after curative hepatectomy for solitary small hepatocellular carcinoma without macroscopic vascular invasion. Journal of Hepato-Biliary-Pancreatic Sciences, 2014, 21, 142-147.	1.4	8
131	Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma. Annals of Oncology, 2014, 25, 1384-1390.	0.6	30
132	Hepatic arterial infusion chemotherapy with cisplatin before radical local treatment of early hepatocellular carcinoma (JIS score $0/1$) improves survival. Annals of Oncology, 2014, 25, 1379-1384.	0.6	11
133	Postoperative recurrence pattern and prognosis of patients with hepatocellular carcinoma, with particular reference to the hepatitis viral infection status. Liver International, 2014, 34, 802-813.	1.9	27
134	Staging, prognostic factors and adjuvant therapy of intrahepatic cholangiocarcinoma after curative resection. Liver International, 2014, 34, 953-960.	1.9	63
135	Clinical significance of therapy using branchedâ€chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma. Hepatology Research, 2014, 44, 149-158.	1.8	34
136	Case series of 17 patients with cholangiocarcinoma among young adult workers of a printing company in Japan. Journal of Hepato-Biliary-Pancreatic Sciences, 2014, 21, 479-488.	1.4	92
137	Longâ€ŧerm survival after two surgical resections of peritoneal metastases from hepatocellular carcinoma with an interval of 4Âyears. Clinical Case Reports (discontinued), 2014, 2, 37-41.	0.2	2
138	Proposal of a new staging system for mass-forming intrahepatic cholangiocarcinoma: a multicenter analysis by the Study Group for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. Journal of Hepato-Biliary-Pancreatic Sciences, 2014, 21, 499-508.	1.4	66
139	Prognostic Impact of Spontaneous Tumor Rupture in Patients With Hepatocellular Carcinoma. Annals of Surgery, 2014, 259, 532-542.	2.1	145
140	Emerging drugs for biliary cancer. Expert Opinion on Emerging Drugs, 2014, 19, 11-24.	1.0	6
141	Salvage treatment for local recurrence of hepatocellular carcinoma after local ablation therapy. Hepatology Research, 2014, 44, E335-45.	1.8	29
142	An artificial neural networking model for the prediction of postâ€hepatectomy survival of patients with early hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 2014-2020.	1.4	24
143	Novel hepatitis <scp>B</scp> virus strain developing due to recombination between genotypes <scp>H</scp> and <scp>B</scp> strains isolated from a <scp>J</scp> apanese patient. Hepatology Research, 2014, 44, 1130-1141.	1.8	6
144	Typical fibrolamellar hepatocellular carcinoma in a Japanese boy: report of a case. Surgery Today, 2014, 44, 1359-1366.	0.7	5
145	Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-na \tilde{A} -ve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. Journal of Gastroenterology, 2014, 49, 138-147.	2.3	73

#	Article	IF	CITATIONS
146	Comparison of the Therapeutic Outcomes Between Surgical Resection and Percutaneous Ablation for Small Hepatocellular Carcinoma. Annals of Surgical Oncology, 2014, 21, 348-355.	0.7	31
147	Surgical treatment for intrahepatic cholangiocarcinoma. Clinical Journal of Gastroenterology, 2014, 7, 87-93.	0.4	16
148	Diagnosis and Surgical Treatment of Intrahepatic Hepatolithiasis Combined with Cholangiocarcinoma. World Journal of Surgery, 2014, 38, 2097-2104.	0.8	15
149	Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma. Hepatology Research, 2014, 44, 1329-1338.	1.8	33
150	The long-term outcomes after curative resection for mass-forming intrahepatic cholangiocarcinoma associated with hepatitis C viral infection: A multicenter analysis by Osaka Hepatic Surgery Study Group. Journal of Surgical Oncology, 2014, 110, 176-181.	0.8	10
151	Ablation of hepatocellular carcinoma. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 897-908.	1.0	56
152	Radiofrequency ablation guided by contrast-enhanced ultrasound for hepatic malignancies: Preliminary results. Clinical Radiology, 2014, 69, 1129-1135.	0.5	21
153	Combined hepatocellular–cholangiocarcinoma producing parathyroid hormone-related protein: report of a case. Surgery Today, 2014, 44, 1577-1583.	0.7	9
154	Recent trends in hepatectomy for elderly patients with hepatocellular carcinoma. Surgery Today, 2014, 44, 1651-1659.	0.7	25
155	Factors affecting survival after resection of intrahepatic cholangiocarcinoma. Surgery Today, 2014, 44, 1847-1854.	0.7	28
156	Associations of daily walking and television viewing time with liver cancer mortality: findings from the Japan Collaborative Cohort Study. Cancer Causes and Control, 2014, 25, 787-793.	0.8	15
157	Efficacy of Hepatic Arterial Infusion Chemotherapy Using 5-Fluorouracil and Systemic Pegylated Interferon α-2b for Advanced Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2014, 21, 3638-3645.	0.7	19
158	Clinicopathologic characteristics of SALL4-immunopositive hepatocellular carcinoma. SpringerPlus, 2014, 3, 721.	1.2	19
159	Hepatic Resection Associated With Good Survival for Selected Patients With Intermediate and Advanced-Stage Hepatocellular Carcinoma. Annals of Surgery, 2014, 260, 329-340.	2.1	382
160	Section 4. Further Expanding the Criteria for HCC in Living Donor Liver Transplantation. Transplantation, 2014, 97, S17-S20.	0.5	9
161	Nationwide Study of 4741 Patients With Non-B Non-C Hepatocellular Carcinoma With Special Reference to the Therapeutic Impact. Annals of Surgery, 2014, 259, 336-345.	2.1	62
162	Outcome of Hepatectomy for Hepatocellular Carcinoma in Elderly Patients With Portal Hypertension. International Surgery, 2014, 99, 153-160.	0.0	8
163	Treatment for hepatocellular carcinoma in <scp>J</scp> apan over the last three decades: Our experience and published work review. Hepatology Research, 2015, 45, 59-74.	1.8	72

#	Article	IF	CITATIONS
164	Proton Therapy: A New Dawn for Gastrointestinal Cancer Treatment., 2015,, 637-646.		0
165	Clear Visualization of Extravasation on Angiography Using Carbon Dioxide in a Case of Hepatocellular Carcinoma Rupture with Unclear Visualization Using Iodine Contrast Agent. Internal Medicine, 2015, 54, 407-410.	0.3	2
166	Long-term prognosis after resection of cryptogenic hepatocellular carcinoma. BMC Surgery, 2015, 15, 115.	0.6	3
167	Anatomical <i>versus</i> non-anatomical resection for hepatocellular carcinoma. British Journal of Surgery, 2015, 102, 776-784.	0.1	115
168	Hepatic Resection as a Safe and Effective Treatment for Hepatocellular Carcinoma Involving a Single Large Tumor, Multiple Tumors, or Macrovascular Invasion. Medicine (United States), 2015, 94, e396.	0.4	110
169	A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases (Basel,) Tj ETQq1 1 0.784314	rgBT/Ove	erlogk 10 Tf 5
170	A Collision Probability Model of Portal Vein Tumor Thrombus Formation in Hepatocellular Carcinoma. PLoS ONE, 2015, 10, e0130366.	1.1	4
171	Role of liver resection in the management of multinodular hepatocellular carcinoma. World Journal of Hepatology, 2015, 7, 2237.	0.8	5
172	Hepatic resection for hepatocellular carcinoma in super-elderly patients aged 80Âyears and older in the first decade of the 21st century. Surgery Today, 2015, 45, 851-857.	0.7	51
173	Hepatic expression of the Sptlc3 subunit of serine palmitoyltransferase is associated with the development of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis. Oncology Reports, 2015, 33, 1657-1666.	1.2	14
174	Hepatic Resection for Hepatocellular Carcinoma with Tumor Thrombus in the Major Portal Vein. Digestive Surgery, 2015, 32, 413-420.	0.6	31
175	Implication of an extremely high preoperative alpha-fetoprotein value (>4,000Âng/mL) for the long-term outcomes of hepatectomy for resectable hepatocellular carcinoma. Surgery, 2015, 157, 223-230.	1.0	2
176	Relative efficacy and safety of simeprevir and telaprevir in treatmentâ€naà ve hepatitis Câ€infected patients in a Japanese population: A Bayesian network metaâ€analysis. Hepatology Research, 2015, 45, E89-98.	1.8	9
177	Macrophage density and macrophage colony-stimulating factor expression predict the postoperative prognosis in patients with intrahepatic cholangiocarcinoma. Surgery Today, 2015, 45, 715-722.	0.7	12
178	The value of systematic lymph node dissection for intrahepatic cholangiocarcinoma from the viewpoint of liver lymphatics. Journal of Gastroenterology, 2015, 50, 913-927.	2.3	70
179	Development of hepatocellular carcinoma in cardiac congestive liver fibrosis: report of a case. Clinical Journal of Gastroenterology, 2015, 8, 143-147.	0.4	1
180	Sentinel Lymph Node Mapping of Liver. Annals of Surgical Oncology, 2015, 22, 1147-1155.	0.7	21
181	A Comparison of the Surgical Outcomes Among Patients With HBV-positive, HCV-positive, and Non-B Non-C Hepatocellular Carcinoma. Annals of Surgery, 2015, 261, 513-520.	2.1	130

#	ARTICLE	IF	CITATIONS
182	Proton beam therapy for unresectable intrahepatic cholangiocarcinoma. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 957-963.	1.4	42
183	Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection. Clinical Journal of Gastroenterology, 2015, 8, 300-305.	0.4	13
184	Hepatocellular carcinoma based on cryptogenic liver disease: The most common nonâ€viral hepatocellular carcinoma in patients aged over 80 years. Hepatology Research, 2015, 45, 441-447.	1.8	14
185	Prognostic Factors and Clinical Characteristics for Hepatocellular Carcinoma Patients with Benign Enlarged Perihepatic Lymph Nodes: a Single-Center Experience from China. Journal of Gastrointestinal Surgery, 2015, 19, 1822-1832.	0.9	3
186	Quantum Dots Based Potential-Resolution Dual-Targets Electrochemiluminescent Immunosensor for Subtype of Tumor Marker and Its Serological Evaluation. Analytical Chemistry, 2015, 87, 9163-9169.	3.2	54
187	Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis. Clinical Drug Investigation, 2015, 35, 751-759.	1.1	26
188	The prognostic values of 12 cirrhosis-relative noninvasive models in patients with hepatocellular carcinoma. Scandinavian Journal of Clinical and Laboratory Investigation, 2015, 75, 73-84.	0.6	12
189	Usefulness of a new inflammation-based scoring system for prognostication of patients with hepatocellular carcinoma after hepatectomy. American Journal of Surgery, 2015, 209, 187-193.	0.9	8
190	Analysis of Recurrence Patterns After Anatomical or Non-anatomical Resection for Hepatocellular Carcinoma. Annals of Surgical Oncology, 2015, 22, 2243-2252.	0.7	46
191	Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. Journal of Gastroenterology, 2015, 50, 350-360.	2.3	144
192	Improved Postoperative Survival for Intraductal- Growth Subtype of Intrahepatic Cholangiocarcinoma. American Surgeon, 2016, 82, 1133-1139.	0.4	10
193	Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma. Cancer Biology and Medicine, 2016, 13, 452.	1.4	35
194	Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis. World Journal of Gastroenterology, 2016, 22, 6851.	1.4	52
195	Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus - Eastern Hepatobiliary Surgical Hospital consensus statement. Oncotarget, 2016, 7, 40816-40829.	0.8	38
196	Impact of clinically significant portal hypertension on surgical outcomes for hepatocellular carcinoma in patients with compensated liver cirrhosis: a propensity score matching analysis. Annals of Hepato-biliary-pancreatic Surgery, 2016, 20, 159.	0.1	6
197	KRAS Mutation as a Potential Prognostic Biomarker of Biliary Tract Cancers. Japanese Clinical Medicine, 2016, 7, JCM.S40549.	1.9	11
198	Report of the 19th followâ€up survey of primary liver cancer in Japan. Hepatology Research, 2016, 46, 372-390.	1.8	125
199	Outcomes of intrahepatic cholangiocarcinoma with portal vein tumor thrombus following hepatic resection. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1330-1335.	1.4	14

#	Article	IF	CITATIONS
200	Is Surgical Resection Justified for Advanced Intrahepatic Cholangiocarcinoma?. Liver Cancer, 2016, 5, 280-289.	4.2	27
201	Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-na $ ilde{A}$ ve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan. Journal of Medical Economics, 2016, 19, 1144-1156.	1.0	19
202	Salvage resection for recurrent or metastatic hepatocellular carcinoma after percutaneous ablation therapy. International Journal of Surgery, 2016, 36, 68-73.	1.1	1
203	Survival outcome of salvage hepatectomy in patients with local, recurrent hepatocellular carcinoma who underwent radiofrequency ablation as their first treatment. Surgery, 2016, 160, 661-670.	1.0	5
204	Impact of operative and peri-operative factors on the long-term prognosis of primary liver cancer patients undergoing hepatectomy. Journal of Huazhong University of Science and Technology [Medical Sciences], 2016, 36, 523-528.	1.0	11
205	Dendritic Cell Immunotherapy Combined with Cytokine-Induced Killer Cells Effectively Suppresses Established Hepatocellular Carcinomas in Mice. Immunological Investigations, 2016, 45, 553-565.	1.0	14
206	Selection criteria for hepatic resection in intermediate-stage (BCLC stage B) multiple hepatocellular carcinoma. Surgery, 2016, 160, 1227-1235.	1.0	67
207	Controversies and evidence of hepatic resection for hepatocellular carcinoma. BBA Clinical, 2016, 6, 125-130.	4.1	16
208	Current Status of Alcoholic Hepatocellular Carcinoma in Japan -Nation-wide Survey in 2014 Acta Hepatologica Japonica, 2016, 57, 538-547.	0.0	1
209	Title is missing!. Acta Hepatologica Japonica, 2016, 57, 45-73.	0.0	23
210	Portal Vein Pressure Change Predicts Posthepatectomy Liver Failure Following Right Lobectomy. International Surgery, 2016, 101, 437-442.	0.0	1
211	Surgical treatment of double primary liver cancer. Medicine (United States), 2016, 95, e4412.	0.4	5
212	Influence of surgical margins on overall survival after resection of intrahepatic cholangiocarcinoma. Medicine (United States), 2016, 95, e4621.	0.4	29
213	Application of imaging fusion combining contrastâ€enhanced ultrasound and magnetic resonance imaging in detection of hepatic cellular carcinomas undetectable by conventional ultrasound. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 822-828.	1.4	39
214	Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan. Liver Cancer, 2016, 5, 190-197.	4.2	122
215	Propensity score-based comparison of hepatic resection and transarterial chemoembolization for patients with advanced hepatocellular carcinoma. Tumor Biology, 2016, 37, 2435-2441.	0.8	22
216	Significant Improvement in Outcomes of Patients with Intrahepatic Cholangiocarcinoma after Surgery. World Journal of Surgery, 2016, 40, 2229-2236.	0.8	24
217	Evaluating the current surgical strategies for hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2016, 10, 341-357.	1.4	7

#	Article	IF	CITATIONS
218	Predictive Value of Conventional Ultrasound and Contrast-Enhanced Ultrasound in Early Recurrence of Hepatocellular Carcinoma after Surgical Resection. Ultrasound in Medicine and Biology, 2016, 42, 1042-1048.	0.7	20
219	Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey. Journal of Gastroenterology, 2016, 51, 586-596.	2.3	49
220	Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing. Journal of Gastroenterology, 2016, 51, 260-270.	2.3	19
221	Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. Journal of Clinical Pathology, 2016, 69, 403-408.	1.0	56
222	Prognostic influence of spontaneous tumor rupture on hepatocellular carcinoma after interval hepatectomy. Surgery, 2016, 159, 409-417.	1.0	46
223	Nonâ€response to daclatasvir and asunaprevir therapy in patients coâ€infected with hepatitis C virus genotypes 1 and 2. Hepatology Research, 2017, 47, 364-367.	1.8	4
224	Assessing the feasibility of clinicopathological features of hepatic resection for hepatocellular carcinoma in patients over 80 years of age. Molecular and Clinical Oncology, 2017, 6, 29-38.	0.4	9
225	A Novel Biomarker-Based Preoperative Prognostic Grading System for Predicting Survival After Surgery for Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2017, 24, 1351-1357.	0.7	28
226	Prognostic impacts of postoperative complications in patients with intrahepatic cholangiocarcinoma after curative operations. International Journal of Clinical Oncology, 2017, 22, 526-532.	1.0	12
227	Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. Liver Cancer, 2017, 6, 204-215.	4.2	159
228	Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients. Advances in Therapy, 2017, 34, 1449-1465.	1.3	14
229	Safety and Efficacy of Irradiation Stent Placement for Malignant Portal Vein Thrombus Combined with Transarterial Chemoembolization for Hepatocellular Carcinoma: A Single-Center Experience. Journal of Vascular and Interventional Radiology, 2017, 28, 786-794.e3.	0.2	35
230	Constraints for symptomatic radiation pneumonitis of helical tomotherapy hypofractionated simultaneous multitarget radiotherapy for pulmonary metastasis from hepatocellular carcinoma. Radiotherapy and Oncology, 2017, 123, 246-250.	0.3	4
231	Multidisciplinary management of intrahepatic cholangiocarcinoma: Current approaches. Surgical Oncology, 2017, 26, 146-152.	0.8	40
232	Preoperative plateletâ€toâ€lymphocyte ratio can predict recurrence beyond the Milan criteria after hepatectomy for patients with hepatocellular carcinoma. Hepatology Research, 2017, 47, 991-999.	1.8	24
233	Role of low-molecular-weight heparins in prevention of thromboembolic complication after transarterial chemoembolization in hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2017, 29, 317-321.	0.8	30
234	Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. Liver Cancer, 2017, 6, 325-336.	4.2	202
235	Cost–utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan. Current Medical Research and Opinion, 2017, 33, 1-10.	0.9	40

#	Article	IF	CITATIONS
236	Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification. World Journal of Surgical Oncology, 2017, 15, 156.	0.8	16
237	Transglutaminase 2 is upregulated in primary hepatocellular carcinoma with early recurrence as determined by proteomic profiles. International Journal of Oncology, 2017, 50, 1749-1759.	1.4	10
238	Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the Barcelona Clinic Liver Cancer treatment algorithms: a review and update. Oncotarget, 2017, 8, 93258-93278.	0.8	27
239	Impact of serum carbohydrate antigen 19â€9 level on prognosis and prediction of lymph node metastasis in patients with intrahepatic cholangiocarcinoma. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1626-1633.	1.4	28
240	Liver resection of hepatocellular carcinoma in patients with portal hypertension and multiple tumors. Hepatology Research, 2018, 48, 433-441.	1.8	14
241	Combined transcatheter arterial chemoembolization and radiofrequency ablation in singleâ€session for solitary hepatocellular carcinoma larger than 7Âcm. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 300-309.	0.7	13
242	Comparison of conservative treatment versus transcatheter arterial embolisation for the treatment of spontaneously ruptured hepatocellular carcinoma. Polish Journal of Radiology, 2018, 83, 311-318.	0.5	6
243	Combined Treatment for Lung Metastasis from Hepatocellular Carcinoma: A Case Report. Explore: the Journal of Science and Healing, 2018, 14, 385-388.	0.4	4
244	Treatment of Na \tilde{A} -ve HCC Combined with Segmental or Subsegmental Portal Vein Tumor Thrombosis: Liver Resection <i>Versus</i> TACE Followed by Radiotherapy. Anticancer Research, 2018, 38, 4919-4925.	0.5	14
245	Application of contrastâ€enhanced ultrasound and enhanced CT in diagnosis of liver cancer and evaluation of radiofrequency ablation. Oncology Letters, 2018, 16, 2434-2438.	0.8	8
246	Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. Liver Cancer, 2019, 8, 121-129.	4.2	159
247	Smoking, Alcohol Consumption, and Risks for Biliary Tract Cancer and Intrahepatic Bile Duct Cancer. Journal of Epidemiology, 2019, 29, 180-186.	1.1	18
248	Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients. Liver Cancer, 2019, 8, 312-325.	4.2	88
249	Liver resection is justified for multinodular hepatocellular carcinoma in selected patients with cirrhosis: A multicenter analysis of 1,066 patients. European Journal of Surgical Oncology, 2019, 45, 800-807.	0.5	12
250	Is disease progression a contraindication for the strategy of portal vein embolization followed by hepatectomy for hepatocellular carcinoma?. Surgery, 2019, 165, 696-702.	1.0	9
251	Outcomes and Prognostic Factors of Spontaneously Ruptured Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2019, 23, 1788-1800.	0.9	30
252	Impact of Advanced Age on Survival in Patients Undergoing Resection of Hepatocellular Carcinoma. Annals of Surgery, 2019, 269, 692-699.	2.1	53
253	Treatment Optimization for Hepatocellular Carcinoma in Elderly Patients in a Japanese Nationwide Cohort. Annals of Surgery, 2019, 270, 121-130.	2.1	48

#	ARTICLE	IF	CITATIONS
254	Rupture of Hepatocellular Carcinoma: A Review of Literature. Journal of Clinical and Experimental Hepatology, 2019, 9, 245-256.	0.4	83
255	Association of inflammatory biomarkers with long-term outcomes after curative surgery for mass-forming intrahepatic cholangiocarcinoma. Surgery Today, 2020, 50, 379-388.	0.7	21
256	Report of the 20th Nationwide followâ€up survey of primary liver cancer in Japan. Hepatology Research, 2020, 50, 15-46.	1.8	111
257	Expression of c-Met in Primary and Recurrent Hepatocellular Carcinoma. Oncology, 2020, 98, 186-194.	0.9	10
258	Identification of a specific ultrasonographic finding for differentiating hepatic angiomyolipoma from hepatocellular carcinoma. Clinical Imaging, 2020, 59, 104-108.	0.8	2
259	Multimodality Imaging of Abdominopelvic Tumors with Venous Invasion. Radiographics, 2020, 40, 2098-2116.	1.4	11
260	Two elder cases of hepatocellular carcinoma adjacent to intrahepatic vessels successfully treated by carbon ion radiotherapy. Clinical Journal of Gastroenterology, 2020, 13, 920-926.	0.4	1
261	The role of hyperthermic intraperitoneal chemotherapy in the treatment of spontaneously ruptured hepatocellular carcinoma: a pilot study. Annals of Translational Medicine, 2020, 8, 1132-1132.	0.7	8
262	Is Macroscopic Portal Vein Tumor Thrombosis of HCC Really an Exclusion for Liver Transplantation?. Journal of Gastrointestinal Cancer, 2020, 51, 1137-1140.	0.6	3
263	Locoregional therapies in patients with recurrent intrahepatic cholangiocarcinoma after curative resection. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482097697.	1.4	3
264	Relationship between outcomes and relative dose intensity of lenvatinib treatment in patients with advanced hepatocellular carcinoma. Liver Research, 2020, 4, 199-205.	0.5	7
265	Stratification of portal vein-invaded hepatocellular carcinoma treated with transarterial chemoembolization monotherapy. Journal of Interventional Medicine, 2020, 3, 201-207.	0.2	0
266	Estimating the price at which hepatitis C treatment with direct-acting antivirals would be cost-saving in Japan. Scientific Reports, 2020, 10, 4089.	1.6	9
267	Impact of Adverse Events on the Progression-Free Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. Drugs - Real World Outcomes, 2020, 7, 141-149.	0.7	33
268	Effect of surgical margin width after RO resection for intrahepatic cholangiocarcinoma: A nationwide survey of the Liver Cancer Study Group of Japan. Surgery, 2020, 167, 793-802.	1.0	36
269	Hepatocellular carcinoma with hilar bile duct tumor thrombus versus hilar Cholangiocarcinoma on enhanced computed tomography: a diagnostic challenge. BMC Cancer, 2020, 20, 54.	1.1	13
270	Renal metastasis from intrahepatic cholangiocarcinoma. International Cancer Conference Journal, 2020, 9, 66-71.	0.2	1
271	Î ³ -Glutamyltranspeptidase as a Prognostic Biomarker in Advanced Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Journal of Vascular and Interventional Radiology, 2021, 32, 419-428.e2.	0.2	7

#	Article	IF	CITATIONS
272	Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study. CardioVascular and Interventional Radiology, 2021, 44, 63-72.	0.9	5
273	Surveillance, Diagnosis, and Treatment Outcomes of Hepatocellular Carcinoma in Japan: 2021 Update. Liver Cancer, 2021, 10, 167-180.	4.2	17
274	Impact of patient age on outcome after resection for hepatocellular carcinoma. BioScience Trends, 2021, 15, 33-40.	1.1	1
275	Randomized controlled study to examine the efficacy of hepatic arterial infusion chemotherapy with cisplatin before radiofrequency ablation for hepatocellular carcinoma. Hepatology Research, 2021, 51, 694-701.	1.8	9
276	Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drugâ€eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma. Hepatology Research, 2021, 51, 482-489.	1.8	6
277	Report of the 21st Nationwide Followâ€up Survey of Primary Liver Cancer in Japan (2010–2011). Hepatology Research, 2021, 51, 355-405.	1.8	54
278	Report of the 22nd nationwide followâ€up Survey of Primary Liver Cancer in Japan (2012–2013). Hepatology Research, 2022, 52, 5-66.	1.8	46
279	第22回å¨å›½åŽŸç™ºæ€§è,癌追跡賿査å±å'Šï¼^2012~2013). Acta Hepatologica Japonica, 202	1962, 251	- 2 599.
280	The Role of Surgical Resection and Liver Transplantation for the Treatment of Intrahepatic Cholangiocarcinoma. Journal of Clinical Medicine, 2021, 10, 2428.	1.0	4
281	Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma – The Changing Tides. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1089-1115.	1.8	28
282	Lung and lymph node metastases from hepatocellular carcinoma: Comparison of pathological aspects. Liver International, 2022, 42, 199-209.	1.9	19
283	Liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis. Journal of Liver Cancer, 2021, 21, 105-112.	0.3	2
284	Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence. Journal of Viral Hepatitis, 2021, 28, 1597-1603.	1.0	5
285	Outcomes of Hepatic Resection for Hepatocellular Carcinoma Associated with Portal Vein Invasion. Journal of Surgical Research, 2021, 266, 269-283.	0.8	5
286	Successful Management of Resuscitative Endovascular Balloon Occlusion of the Aorta for Hemorrhagic Shock Due to Ruptured Hepatocellular Carcinoma. Internal Medicine, 2022, , .	0.3	0
288	Liver resection in cirrhosis. , 2012, , 1537-1543.e2.		2
289	Resection of Hepatocellular Carcinoma Recurring in the Diaphragm after Right Hepatic Lobectomy. Journal of Nippon Medical School, 2011, 78, 30-33.	0.3	2
290	Frequency of and Predictive Factors for Vascular Invasion after Radiofrequency Ablation for Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e111662.	1.1	24

#	Article	IF	CITATIONS
291	A Novel Simple Assay System to Quantify the Percent HCV-RNA Levels of NS5A Y93H Mutant Strains and Y93 Wild-Type Strains Relative to the Total HCV-RNA Levels to Determine the Indication for Antiviral Therapy with NS5A Inhibitors. PLoS ONE, 2014, 9, e112647.	1.1	53
292	Simultaneous multitarget radiotherapy using helical tomotherapy and its combination with sorafenib for pulmonary metastases from hepatocellular carcinoma. Oncotarget, 2016, 7, 48586-48599.	0.8	14
293	Clinical Benefits of Lymph Node Dissection in Intrahepatic Cholangiocarcinoma: A Retrospective Single-institution Study. Anticancer Research, 2017, 37, 2673-2677.	0.5	9
294	CD44 Expression Is a Prognostic Factor in Patients with Intrahepatic Cholangiocarcinoma After Surgical Resection., 2017, 37, 5701-5705.		11
295	Classification and Current Treatment of Hepatocellular Carcinoma. American Journal of Interventional Radiology, 0, 2, 8.	0.0	3
296	第18回å"国原発性è,癌追跡調査å±å'Šï¼^2004~2005). Acta Hepatologica Japonica, 20	10p5d, 46	0-\$24.
297	第20回 å¨å›½aŽŸç™ºæ€§è,癌追跡賿査å±åʻŠï¼^2008ï½zž2009). Acta Hepatologica Japonica, 20)19).6 0, 25	58-2293.
298	Features of hepatocellular carcinoma in cases with autoimmune hepatitis and primary biliary cirrhosis. World Journal of Gastroenterology, 2009, 15, 231.	1.4	26
299	Efficacy of surgical resection in management of isolated extrahepatic metastases of hepatocellular carcinoma. World Journal of Gastroenterology, 2009, 15, 5481.	1.4	59
300	Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China. World Journal of Gastroenterology, 2010, 16, 264.	1.4	46
301	Factors associated with the overall survival of elderly patients with hepatocellular carcinoma. World Journal of Gastroenterology, 2012, 18, 1926.	1.4	19
302	Strategy for improving survival and reducing recurrence of HCV-related hepatocellular carcinoma. World Journal of Gastroenterology, 2013, 19, 6127.	1.4	18
303	Routine lymph node dissection may be not suitable for all intrahepatic cholangiocarcinoma patients: Results of a monocentric series. World Journal of Gastroenterology, 2013, 19, 9084.	1.4	41
304	Recent advances in the surgical treatment of hepatocellular carcinoma. World Journal of Gastroenterology, 2014, 20, 14381.	1.4	81
305	Prognosis after resection for hepatitis B virus-associated intrahepatic cholangiocarcinoma. World Journal of Gastroenterology, 2015, 21, 935.	1.4	26
306	Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. World Journal of Gastroenterology, 2019, 25, 4360-4382.	1.4	83
308	Redefining the T1 category of the 8th American Joint Committee on Cancer Staging System for intrahepatic cholangiocarcinoma: A SEER database analysis. Oncology Letters, 2020, 19, 527-532.	0.8	3
309	Synchronous development of HCC and CCC in the same subsegment of the liver in a patient with type C liver cirrhosis. World Journal of Hepatology, 2009, 1, 103.	0.8	16

#	Article	IF	CITATIONS
310	Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evidence. World Journal of Hepatology, 2018, 10, 433-447.	0.8	31
311	Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma. World Journal of Hepatology, 2020, 12, 693-708.	0.8	46
312	Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World Journal of Hepatology, 2010, 2, 58.	0.8	53
313	Surgical approach for hepatitis C virus-related hepatocellular carcinoma. World Journal of Hepatology, 2015, 7, 70.	0.8	5
314	Hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus. World Journal of Hepatology, 2017, 9, 1296-1304.	0.8	11
315	Assessment of the Surveillance Interval at 1 Year after Curative Treatment in Hepatocellular Carcinoma: Risk Stratification. Gut and Liver, 2018, 12, 571-582.	1.4	6
316	Liver transplantation and aging. World Journal of Transplantation, 2020, 10, 256-266.	0.6	9
317	Liver Resection. , 2009, , 134-145.		0
318	Local Ablation Therapy., 2009,, 104-113.		0
319	A case of biliary cystadenocarcinoma exhibiting gastric foveolar-type mucin. Acta Hepatologica Japonica, 2010, 51, 127-134.	0.0	0
320	Two cases of successfully treated after endoscopic biliary drainage for obstructive jaundice in hepatocellular carcinoma. Progress of Digestive Endoscopy, 2010, 76, 130-131.	0.0	0
321	99mTc-Galactosyl Syalil Albumin (GSA) Scintigram Adjusts Hepatic Resection Range in ICG Based Estimation. Hepato-Gastroenterology, 2011, 58, 2058-61.	0.5	7
322	Combined surgical procedure for hepatocellular carcinoma complicated with portal hypertension: an observation of clinical effectiveness. Academic Journal of Second Military Medical University, 2011, 31, 915-917.	0.0	0
323	Percutaneous methods for ablating liver tumors. , 2012, , 1376-1388.e3.		O
324	Current Status of Hepatocellular Carcinoma Treatment in Japan. Clinical Drug Investigation, 2012, 32, 15-23.	1.1	3
326	A Case of Solitary Lymph Node Metastasis Strongly Positive for PET Following Radiofrequency Ablation for Hepatocellular Carcinoma. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of) Tj ETQq1	1 0. 08431	41rgBT /Ove
327	A Case of Peritoneal Metastasis from Hepatocellular Carcinoma That Was Treated with Balloon-Occluded Transarterial Chemoembolization. Journal of the Nihon University Medical Association, 2015, 74, 308-310.	0.0	0
328	Current advances made in the surgical treatment of hepatocellular carcinoma. International Surgery Journal, 2015, 2, 147.	0.0	O

#	Article	IF	Citations
329	Biomarkers for Hepatocellular Carcinoma in East Asia. Biomarkers in Disease, 2017, , 901-925.	0.0	0
330	Laparoscopic Left Hepatectomy for Ruptured Hepatocellular Carcinoma Controlled After Transcatheter Arterial Embolization: Case Report and Review of the Literature. In Vivo, 2018, 32, 659-662.	0.6	8
331	Types of Segment-Oriented Hepatic Resection by the Glissonean Pedicle Approach., 2019,, 49-260.		0
332	Hepatocellular cancer and liver transplantation: necessity to go from chaos to order. Alʹmanah KliniÄeskoj Mediciny, 2018, 46, 552-559.	0.2	1
333	8. Non-B, Non-C Liver Cancer in Japan: Present Status and Perspective. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 1912-1917.	0.0	0
334	第21回 å¨å›½åŽŸç™ºæ€§è,癌追跡調査å±å'Šï¼^2010~2011). Acta Hepatologica Japonica, 20	02 0).6 1,64	15-6 91.
335	Combined Transarterial Chemoembolization and External Beam Radiotherapy in a Patient with Recurrent Huge Hepatocellular Carcinoma after Hepatic Resection. Journal of Liver Cancer, 2020, 20, 90-97.	0.3	0
336	Improved Postoperative Survival for Intraductal-Growth Subtype of Intrahepatic Cholangiocarcinoma. American Surgeon, 2016, 82, 1133-1139.	0.4	5
338	Pooled Analysis of the Associations between Body Mass Index, Total Cholesterol, and Liver Cancer-related Mortality in Japan. Asian Pacific Journal of Cancer Prevention, 2018, 19, 2089-2095.	0.5	3
339	Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study. Frontiers in Oncology, 2021, 11, 729764.	1.3	28
340	Potential of PALBIâ€₹ score as a prognostic model for hepatocellular carcinoma in alcoholic liver disease. JGH Open, 2022, 6, 36-43.	0.7	3
342	A Glycoformâ€Resolved Dualâ€Modal Ratiometric Immunoassay Improves the Diagnostic Precision for Hepatocellular Carcinoma. Angewandte Chemie - International Edition, 2022, 61, .	7.2	20
343	New Insights Into a Classification-Based Microvascular Invasion Prediction Model in Hepatocellular Carcinoma: A Multicenter Study. Frontiers in Oncology, 2022, 12, 796311.	1.3	1
344	A Glycoformâ€Resolved Dualâ€Modal Ratiometric Immunoassay Improves the Diagnostic Precision for Hepatocellular Carcinoma. Angewandte Chemie, 2022, 134, .	1.6	5
345	Postoperative recurrence with right cervical lymph node metastasis in hepatocellular carcinoma: a case report. Surgical Case Reports, 2021, 7, 260.	0.2	2
346	Clinicopathological Analysis of Non-B Non-C Hepatocellular Carcinoma Focusing on Cellular Proliferation. Anticancer Research, 2022, 42, 449-457.	0.5	2
347	Can hepatocellular carcinoma (HCC) produce unconventional metastases? Four cases of extrahepatic HCC. Tumori, 2013, 99, e19-23.	0.6	9
348	Descriptive epidemiology of biliary tract cancer incidence and geographic variation in Japan. European Journal of Cancer Prevention, 2022, Publish Ahead of Print, .	0.6	1

#	Article	IF	CITATIONS
349	Indications for lymph node dissection in hepatocellular carcinoma. Khirurgiya, 2022, , 5.	0.0	0
350	Clinical Profile, Patterns of Care & Divide to Guidelines in Patients with Hepatocellular Carcinoma: Prospective multi-center Study. Journal of Clinical and Experimental Hepatology, 2022, 12, 1463-1473.	0.4	4
351	Conversion Therapy of Large Unresectable Hepatocellular Carcinoma With Ipsilateral Portal Vein Tumor Thrombus Using Portal Vein Embolization Plus Transcatheter Arterial Chemoembolization. Frontiers in Oncology, 0, 12, .	1.3	1
352	Rethinking Liver Fibrosis Staging in Patients with Hepatocellular Carcinoma: New Insights from a Large Two-Center Cohort Study. Journal of Hepatocellular Carcinoma, 0, Volume 9, 751-781.	1.8	O
353	Clinical analysis of deceased donor liver transplantation in the treatment of hepatocellular carcinoma with segmental portal vein tumor thrombus: A long-term real-world study. Frontiers in Oncology, 0, 12, .	1.3	2
354	The Prognostic Value of Baseline Clinical and Radiologic Imaging Features in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab. Journal of Hepatocellular Carcinoma, 0, Volume 9, 913-927.	1.8	3
355	The properties and health hazards from early nuclear weapon fallout: The Castle Bravo incident revisited. Radioprotection, 2022, 57, 289-304.	0.5	3
356	Perioperative factors related to the prognosis of elderly patients with hepatocellular carcinoma. European Journal of Medical Research, 2022, 27, .	0.9	0
357	Two cases of hepatocellular carcinoma successfully treated by carbon ion radiotherapy after atezolizumab plus bevacizumab treatment. Clinical Journal of Gastroenterology, 2023, 16, 407-415.	0.4	2
358	Aggrephagy-related LncRNAs index: A predictor for HCC prognosis, immunotherapy efficacy, and chemosensitivity. Technology and Health Care, 2023, 31, 1429-1449.	0.5	1
361	Biomarkers for Hepatocellular Carcinoma in East Asia. Biomarkers in Disease, 2015, , 1-25.	0.0	0
373	Glycan-specific molecularly imprinted polymers towards cancer diagnostics: merits, applications, and future perspectives. Chemical Society Reviews, 2024, 53, 1870-1891.	18.7	O